Streetbeat News

CCAP

Crescent Capital BDC, Inc.

https://www.crescentbdc.com

Industry

Asset Management

Crescent Capital BDC, Inc. is as a business development company private equity / buyouts and loan fund. It specializes in directly investing. It specializes in middle market. The fund seeks to invest in United States.

Open

19.03

Mkt cap

706M

Volume

60K

High

19.15

P/E Ratio

7.45

52-wk high

19.63

Low

19.01

Div yield

0.11

52-wk low

15.91

Keefe, Bruyette & Woods analyst Ryan Lynch maintains an Outperform rating on Crescent Capital BDC (NASDAQ:CCAP) and raises the price target from $18.5 to $19.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2024 | 1:00 pm

Wells Fargo analyst Finian O'Shea maintains an Equal-Weight rating on Crescent Capital BDC (CCAP) and raises the price target from $16.5 to $18.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 1:41 pm

Raymond James analyst Robert Dodd maintains an Outperform rating on Crescent Capital BDC (NASDAQ:CCAP) and raises the price target from $18 to $19.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 5:00 pm

Crescent Capital BDC (CCAP) reported Q1 earnings of $0.63 per share, surpassing the $0.58 estimate, with sales of $50.361M exceeding the $47.696M forecast, marking a 28.21% increase from last year.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 8:48 pm

The article highlights notable value stocks in the financial services sector, focusing on companies with low P/E ratios, indicating potential undervaluation. Crescent Capital BDC, Mid Penn Bancorp, Orrstown Finl Servs, Orange County Bancorp, and United Security are featured for their recent financial performance, including earnings per share and dividend yields.

Portfolio Pulse from Benzinga Insights

March 07, 2024 | 2:47 pm

Crescent Capital BDC (CCAP) reported Q4 2023 adjusted EPS of $0.61, surpassing the $0.57 estimate, with sales of $50M beating the $47.73M estimate, marking a 44.51% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 10:04 pm

The article lists companies scheduled to report their earnings on February 21, 2024, including their expected earnings per share and revenue. It covers a wide range of industries and includes both companies expected to report profits and losses.

Portfolio Pulse from Benzinga Insights

February 21, 2024 | 10:09 am

Crescent Capital BDC (NASDAQ:CCAP) is scheduled to release its quarterly earnings report on 2024-02-21, with analysts expecting an EPS of $0.57. The company's historical performance shows a pattern of beating EPS estimates, which has occasionally led to positive stock price movements the following day. Shares of CCAP have increased by 11.03% over the last 52 weeks, indicating a generally positive outlook from long-term shareholders ahead of the earnings announcement.

Portfolio Pulse from Benzinga Insights

February 20, 2024 | 6:01 pm

Wells Fargo analyst Finian O'Shea has maintained an Equal-Weight rating on Crescent Capital BDC (NASDAQ:CCAP) and increased the price target from $16 to $16.5. This adjustment reflects a modestly positive outlook on the company's stock, suggesting that Wells Fargo sees some potential for growth or improvement in CCAP's market performance.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 2:52 pm

Wall Street analysts have updated their price targets and ratings for several stocks. Citigroup upgraded HP Inc. (HPQ) to Buy and raised its price target, resulting in a 2.2% rise in HP's shares. UBS upgraded Noah Holdings (NOAH) to Buy, with shares up 1.6% in pre-market trading. Piper Sandler upgraded Health Catalyst (HCAT) to Overweight despite a price target cut. AXIS Capital (AXS) was upgraded by Keefe, Bruyette & Woods to Outperform with a higher price target. HC Wainwright maintained a Buy rating on Nouveau Monde Graphite (NMG) but lowered its price target. Wells Fargo downgraded Barings BDC (BBDC) and Crescent Capital BDC (CCAP) to Equal-Weight with reduced price targets. B of A Securities downgraded Paramount Group (PGRE) to Underperform with a lower price target. Barclays downgraded Waters Corporation (WAT) to Underweight and reduced its price target. Goldman Sachs maintained a Neutral rating on GoodRx Holdings (GDRX) but cut its price target.

Portfolio Pulse from Lisa Levin

November 13, 2023 | 1:32 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.